Scientists unravel the cause behind osteoarthritis

Image
Press Trust of India Washington
Last Updated : Jan 20 2013 | 6:57 AM IST

"Clinically, scientists have focused on trying to understand how cartilage and joints degenerate in osteoarthritis. But no one knows why it hurts," said Dr Anne-Marie Malfait, from the Rush University Medical Center.

Malfait and her colleagues took a novel approach to unravelling molecular pathways of OA pain in a surgical mouse model exhibiting the slow, chronically progressive development of the disease.

They were able to monitor development of both pain behaviours and molecular events in the sensory neurons of the knee and correlate the data from repeated observations over an extended period.

"This method essentially provides us with a longitudinal 'read-out' of the development of OA pain and pain-related behaviours, in a mouse model," Malfait said.

The researchers assessed development of pain-related behaviours and concomitant changes in dorsal root ganglia (DRG), nerves that carry signals from sensory organs toward the brain.

They found that a chemokine known as monocyte chemo-attractant protein (MCP)-1 and its receptor, chemokine receptor 2 (CCR2), are central to the development of pain associated with knee OA.

Monocyte chemo-attractant protein-1 regulates migration and infiltration of monocytes into tissues where they replenish infection-fighting macrophages. Previous research has shown that MCP-1/CCR2 are central in pain development following nerve injury.

In the study, following surgery the laboratory mice developed mechanical allodynia that lasted 16 weeks. Levels of MCP-1, CCR2 mRNA and protein were temporarily elevated, and neuronal signalling activity increased in the DRG at eight weeks after surgery.

This result correlated with the presentation of movement-provoked pain behaviours which were maintained up to 16 weeks.

According to the Arthritis Foundation, an estimated 27 million Americans live with OA, but, despite the frequency of the disease, its cause is still not completely known and there is no cure.

  

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 28 2012 | 3:35 PM IST

Next Story